DJ Short explains why Nicholas Castellanos is a strong rebound candidate for fantasy managers after struggling down the stretch in 2020.
DJ Short explains why Nicholas Castellanos is a strong rebound candidate for fantasy managers after struggling down the stretch in 2020.
Clear Cannabis Inc. (CCI), master licensor of legacy cannabis concentrates brand The Clear™, has announced a partnership with the vertically-integrated cannabis company Trucenta to bring The Clear brand to Michigan. The Clear was previously available in Michigan’s medical cannabis market, however, this partnership will mark the brand’s debut in the adult-use market.
The "Pharmaceutical Drugs and Biologics Logistics Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery" report has been added to ResearchAndMarkets.com's offering.
Silicon Labs (NASDAQ: SLAB), a leading provider of silicon, software and solutions for a smarter, more connected world, announces its new standards-driven Wi-SUN® technology, opening the door to new Internet of Things (IoT) market opportunities and accelerating smart city application development. Silicon Labs' certified Wi-SUN solution combines the industry-leading EFR32 hardware platform, full-featured IPv6 mesh stack, and advanced development tools to enable secure wireless connectivity for a broad range of applications, from advanced metering infrastructure (AMI) to street lighting networks, asset management and smart city sensors such as parking, air quality and waste management.
Alliant Insurance Services has announced Abe Freeland has joined the company as Executive Vice President, Real Estate.
Silicon Labs (NASDAQ: SLAB), a leading provider of silicon, software and solutions for a smarter, more connected world, today announced that it plans to release first quarter 2021 financial results on Wednesday, April 28, 2021. An earnings conference call will follow the release at 7:30 a.m. Central Time. The call will be webcast from the Investor Relations section of the company's website at silabs.com.
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has contracted with University of California Health (UC Health) to provide the Sectra VNA, universal viewer, and worklist manager to its academic medical centers. UC San Diego Health is the first of the UC Health campuses to order and deploy the Sectra Enterprise Imaging solution of which Sectra will be the cross-departmental workflow engine and long-term archive for all imaging. Additionally, all breast radiologists, surgeons, pathologists, and orthopedists will utilize Sectra for viewing, diagnostics, surgical planning, and collaboration.
Natrol, a leading vitamins, minerals and supplements brand, today announced the launch of Natrol Sleep+, a line of innovative sleep aid gummies that are drug free and combine melatonin* and secondary ingredients with immune health, calm, and beauty benefits, each uniquely formulated to plus up your sleep. As more and more people seek healthy self-care products, this new line of sleep supplements from Natrol will help provide restful and revitalizing sleep.+
Iterion Therapeutics, Inc., a venture-backed, clinical stage biotechnology company developing novel cancer therapeutics, announced today that it has confirmed the safety of Tegavivint, a novel, potent and selective nuclear beta-catenin inhibitor, after completing enrollment and dosing the final patient in a multicenter Phase 1/2a dose expansion clinical study of Tegavivint in patients with desmoid tumors.
SkinnyDipped, known for insanely delicious, thinly-dipped almonds, peanuts and cashews, is making waves in the candy category with the launch of drool-worthy chocolate bars and peanut butter cups with a fraction of the sugar and no dirty secrets. The brand's new offerings are more delicious than their full-sugar counterparts but have up to 79% less sugar than leading brands and are made without stevia or sugar alcohols.
Sigma Computing, an innovator in cloud analytics and business intelligence, today announced that TruSight has performed a comprehensive risk assessment of the company’s platform and made it available to financial institutions considering Sigma. The completed assessment provides high-quality, fully validated data on the Sigma platform based on a standardized, industry-backed control assessment methodology. Sigma’s decision to undergo the assessment demonstrates the company’s commitment to meeting data security industry control standards and providing transparency into its control environment, ensuring that customers can be confident when selecting Sigma.
Today Instructure announced new MasteryView Assessments, a collection of valid and reliable formative assessments for schools developed by curriculum experts to measure learning loss. MasteryView Assessments are short, pre-built evaluations aligned to key state learning standards that schools can utilize through MasteryConnect, an assessment management system deeply integrated into Instructure's Canvas LMS. Districts can purchase MasteryView Assessments with funds designated in the recent federal stimulus packages to help students close learning gaps caused by the COVID-19 pandemic.
Amylyx announced that long-term survival data from the CENTAUR trial were selected for an oral plenary session at the 2021 AAN Annual Meeting.
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Plug Power Inc. (NASDAQ: PLUG) shares. Investors, who purchased shares of Plug Power Inc. (NASDAQ: PLUG) prior to November 2020 and continue to hold any of their NASDAQ: PLUG shares, have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554. On March 8, 2021, a lawsuit was filed against Plug Power Inc. over alleged violations of securities laws. The plaintiff alleged that the defendants failed to disclose to investors that the Company would be unable to timely file its 2020 annual report due to delays related to the review of classification of certain costs and the recoverability of the right to use assets with certain leases, that the Company was reasonably likely to report material weaknesses in its internal control over financial reporting, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Those who purchased Plug Power Inc. (NASDAQ: PLUG) shares should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 email@example.com 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon.
- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines in the treatment of ADHD, a ~$9 billion U.S. market1 PHILADELPHIA, PA, April 13, 2021 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of CNS disorders, today provided a clinical program update for its lead program, ADAIR, a proprietary abuse-deterrent formulation of immediate-release (IR) dextroamphetamine currently in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. “Prescription stimulant abuse is a growing, serious issue with more than five million Americans misusing and abusing ADHD prescriptions stimulants on an annual basis. We believe ADAIR, if approved, has the potential to help address this significant problem by making it difficult for individuals to manipulate the drug. Our proprietary immediate release formulation has been shown in studies to behave as intended when taken orally, but is difficult to prepare for snorting or injecting,” commented David Baker, President & Chief Executive Officer of Vallon. Vallon is currently conducting its pivotal intranasal human abuse liability study, which is expected to be the final clinical trial prior to NDA filing. This ongoing SEAL study (Study to Evaluate the Abuse Liability, Pharmacokinetics, Safety and Tolerability of an Abuse-Deterrent d-Amphetamine Sulfate Immediate Release Formulation), is a pivotal randomized, double-blind, double dummy, placebo and active-controlled 4-period, 4-way crossover assessing the abuse potential of ADAIR compared to dextroamphetamine administered intranasally in recreational drug abusers with past history of snorting stimulants. “Through the use of the 505(b)(2) regulatory pathway, we expect to leverage much of the existing data for dextroamphetamine, which has been demonstrated to be an effective treatment for ADHD and narcolepsy,” added Dr. Timothy Whitaker, Vallon’s Chief Medical Officer. “Our ongoing SEAL study is designed to evaluate the safety and abuse liability of ADAIR by recreational drug users. We are pleased with the progress of the study and remain on track with our expectations to report topline results in the second half of this year, which have the potential to support our NDA filing in the second quarter of 2022.” The SEAL study will assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of manipulated ADAIR 30mg when compared to crushed d-amphetamine sulfate and placebo. The primary PD endpoint is mean maximum (Emax) Drug Liking on a bipolar 100mm visual analog scale, a standard endpoint used in human abuse liability studies. To date, two cohorts of subjects have been screened, qualified, and completed the treatment phase of the study. Enrollment in the study remains ongoing. A total of 64 subjects demonstrating a confirmed positive response to stimulants are planned to enter the treatment phase. Safety will be assessed via adverse events, vital signs, ECGs, clinical laboratory tests and Columbia Suicide Severity Rating Scale (C-SSRS). For more information about the study, please visit clinicaltrials.gov and reference identifier: NCT04647903. About ADAIR ADAIR (Abuse Deterrent Amphetamine Immediate Release) is an investigational new drug; a novel, patented formulation of dextroamphetamine designed to deter attempts to crush and snort it or take it by other non-oral routes that can produce a greater “high.” Dextroamphetamine has been used clinically for more than 50 years. It is the same active ingredient used in FDA-approved products, such as Adderall®, Dexedrine®, and Vyvanse®. ADAIR is not approved by the FDA. ADAIR is also being developed for Europe and the UK through a license and collaboration agreement with MEDICE Arzneimittel Pütter GmbH, a leader in the European ADHD market. About Vallon Pharmaceuticals Inc. Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy. For more information about the company, please visit www.vallon-pharma.com or connect with us on LinkedIn or Twitter. Forward Looking Statements This press release contains “forward-looking statements” that are based on Vallon’s current expectations and subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, without limitation, Vallon’s ability to execute its business plan, continue its growth and fund its ongoing business activities as planned, Vallon’s ability to develop and commercialize its product candidates, expectations related to results of clinical trials and studies, Vallon’s expectations with respect to the important advantages it believes its abuse-deterrent formulation of drugs have over similar drugs in the market, and the growing need for abuse-deterrent formulations of drugs, Vallon’s ability to utilize the 505(b)(2) regulatory pathway, and Vallon’s ability to obtain FDA approval of ADAIR and its other product candidates. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” "will,” “would,” or the negative of these words or other similar expressions. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Item 1A. Risk Factors” in our Annual Report on Form 10-K, filed with the U.S. Securities and Exchange Commission on March 29, 2021. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law. References and links to websites have been provided for convenience, and the information contained on any such website is not a part of, or incorporated by reference into, this press release. Vallon is not responsible for the contents of third-party websites. Investor Contact:JTC Team, LLCJenene Thomas(833) firstname.lastname@example.org 1 IQVIA, NSP, 2019
Loughborough, England, April 13, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced the launch of its BEAT®diabetes app on the GooglePlay and iOS platforms. The BEATdiabetes app, which is publicly available through the Google Play store and Apple’s app store provides predictive information that supplies the user suggestions such as smart eating choices, exercise and other potential lifestyle changes over the long term based on information provided by the user. It also features continuous one-on-one support through its AI avatar, Lena, who learns about user habits and regularly becomes more familiar with each user. As new information is processed, Lena offers feedback and encouragement as well as helpful ideas to help users not only improve their health, but potentially reverse Type 2 diabetes. The program is based on an in-clinic program originally developed and validated at the Joslin Diabetes Center. The Company is also beginning pilot programs that include its proprietary proBEAT™ monitor, a non-invasive, daily-wear glucose monitoring patch, synced with the BEAT®diabetes program. proBEAT™ is a flexible wear patch, which provides feedback and actionable insights to users to better understand how diet and lifestyle adjustments might impact blood glucose fluctuations, empowering its users with knowledge that can lead to smarter decisions and improved overall health and well-being. “We believe that the BEAT®diabetes app offers a significant new path toward better lifestyle management with the overall aim of providing a better tool for improved management and potential reversal of Type 2 diabetes,” commented Dr. Faz Chowdhury, Nemaura’s Chief Executive Officer. “In addition, we believe our pilot program which includes our proBEAT™ non-invasive glucose sensor ushers in a new era in the development of life management tools that have been scientifically validated and utilize a personalized coaching method that combines a digital platform with data from a unique non-invasive device. We have initially adopted a business-to-business model and are actively exploring a range of options for broad distribution of this combined program through U.S. insurers and employee wellness programs. The sensor technology provides us with a unique position in this market, at a competitive price point. We look forward to discussing further distribution of the proBEAT™ monitor and associated programs as we progress our commercial initiatives.” For additional information access the program website at www.beatdiabetes.life. About Nemaura Medical, Inc. Nemaura Medical Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes. Nemaura has submitted a PMA (Premarket Approval Application) for sugarBEAT® to the U.S. FDA. proBEAT™ combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service and has been launched in the U.S. as a general wellness product as part of its BEAT®diabetes program. The Company sits at the intersection of the global Type 2 diabetes market that is expected to reach nearly $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable health-tech sector for weight loss and wellness applications that is estimated to reach $60 billion by 2023. For more information, please visit www.NemauraMedical.com. Cautionary Statement Regarding Forward-Looking Statements: The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, the launch of proBEAT™ in the US, risks related to regulatory status and the failure of future development and preliminary marketing efforts, Nemaura’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Nemaura and its partners’ ability to develop, market and sell proBEAT™, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to both proBEAT™ digital health, and sugarBEAT®. There can be no assurance that the company will be able to reach a part of or any of the global market for CGM with its products/services. The FDA reserves the right to re-evaluate their decision that proBEAT™ qualifies as a general wellness product should it become aware of any issues such as skin irritation or other adverse events from the device, as well as any misuse impacting patient safety, and any other reason as the FDA may see fit at its discretion to determine the product does not fit the definition of a general wellness product. These and other risks and uncertainties are identified and described in more detail in Nemaura’s filings with the United States Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the most recently completed fiscal year, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Nemaura undertakes no obligation to publicly update or revise any forward-looking statements. Contact: Jules Abraham CORE IR 917-885-7378 email@example.com
Boliden will announce its Interim Report for the first quarter 2021 on Tuesday 27 April at 07.45 (CET). A press and analyst conference will be held on the same day at 09.30, which also can be followed via webcast and telephone.
Lexitas, a leading provider of technology-enabled litigation services and a portfolio company of funds advised by Apax, announced its acquisition of Alaris. Headquartered in St. Louis, with seven additional regional offices, Alaris is a litigation support company providing court reporting, trial support and alternative dispute resolution services. It is one of the largest and most successful firms in the Midwest, with market-leading clients and some of the best independent contractors in the industry.
Tachyum Shows How to be Green in Debut Newsletter
Napatech™ (OSLO: NAPA.OL), the leading provider of programmable Smart Network Interface Cards (SmartNICs), today announced that it has joined the Kinetic Edge Alliance (KEA), the edge computing ecosystem hosted by Vapor IO. Vapor IO's Kinetic Edge platform is the first fully-integrated hardware and software system for edge co-location, exchange and networking services.
World Centric® announced today Leaf+, the first all-natural, 100% plant-based, fully compostable, innovative alternative solution to fluorinated chemicals such as polyfluoroalkyl substances (PFAS) in disposable fiber tableware. Combining cutting-edge technology with an all-natural, proprietary application, the World Centric Leaf+ solution is PFAS free, oil-resistant, food-grade, and suitable for hot and cold use, an industry first.